<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356043</url>
  </required_header>
  <id_info>
    <org_study_id>130HPS11D</org_study_id>
    <nct_id>NCT01356043</nct_id>
  </id_info>
  <brief_title>CKD-828 Drug Interaction Study (S-amlodipine)</brief_title>
  <official_title>A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate the Pharmacokinetic Drug Interaction and Safety of S-amlodipine Between Free Combination of S-amlodipine and Telmisartan and S-amlodipine Monotherapy in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Pharmacokinetic drug interaction and safety of
      S-amlodipine between free combination of S-amlodipine and Telmisartan and S-amlodipine
      monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>S-amlodipine AUC</measure>
    <time_frame>0, 192, 193, 194, 195, 196, 197, 198, 199, 200, 202, 204, 206, 216 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>S-amlodipine Cmax</measure>
    <time_frame>0, 192, 193, 194, 195, 196, 197, 198, 199, 200, 202, 204, 206, 216 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-amlodipine Tmax</measure>
    <time_frame>0, 192, 193, 194, 195, 196, 197, 198, 199, 200, 202, 204, 206, 216 hr</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Free combination of S-amlodipine and Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-amlodipine monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 5mg,Telmisartan 80mg</intervention_name>
    <description>S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)</description>
    <arm_group_label>Free combination of S-amlodipine and Telmisartan</arm_group_label>
    <other_name>Anydipine S 5mg, Micardis 80mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 5mg</intervention_name>
    <description>S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)</description>
    <arm_group_label>S-amlodipine monotherapy</arm_group_label>
    <other_name>Anydipine S 5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 20 aged and 50 aged in healthy males

          -  Weight more than 55kg, BMI 19kg/m2-26kg/m2 at the period of screening

          -  100mmHg ≤ sit SBP &lt; 140mmHg and 60mmHg ≤ sit DBP &lt; 90mmHg and 50 per/min ≤ Pulse rate
             &lt; 95 per/min

          -  AST, ALT, Total bilirubin &lt; UNL x 1.5

          -  Signed the informed consent from prior to the study participation

        Exclusion Criteria:

          -  Have history of significant hepatic, renal, gastrointestinal, pulmonary,
             musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases

          -  Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer) or
             surgery(except for Appendectomy, Hernia repair) affected by the absorption of
             medications

          -  galactose intolerance or Lapp lactase deficiency or glucose-galactose malabsorption

          -  Hypersensitivity reactions to drugs or clinically significant hypersensitivity
             reactions in the history of telmisartan or Amlodipine

          -  drug abuse, or have a history of drug abuse showed a positive for the Triage TOX drug
             on urine : amphetamine, barbiturate, cocaine, opiates, benzodiazepines,
             THC(cannabinoids), methadone etc.

          -  Subject who takes herbal medicine within 30 days, ethical drug within 14 days, OTC
             within 7 days before the beginning of study treatment

          -  unusual diet affected by the absorption, distribution, metabolism, excretion of
             medications

          -  Subject who treated with any investigational drugs within 90 days before the beginning
             of study treatment

          -  Previously donate whole blood within 60 days or component blood within 30 days or
             transfusion within 30 days

          -  Subject who takes inhibitors and inducers of drug metabolizing enzyme(Barbiturates
             etc.) within 30 days

          -  A heavy caffeine consumer (caffeine &gt; 5 units/day)

          -  A heavy alcohol consumer (alcohol &gt; 21 units/week, 1 unit=pure alcohol 10mL) or cannot
             stop drinking

          -  A heavy smoker (cigarette &gt; 20 cigarettes per day)

          -  Positive for Hepatitis B, Hepatitis C, HIV or syphilis

          -  An impossible one who participates in clinical trial by investigator's decision
             including laboratory test result, EKG result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun S Bae, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>August 29, 2011</last_update_submitted>
  <last_update_submitted_qc>August 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jin Kim/ Director</name_title>
    <organization>Clinical Research Department</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

